Véronique M.
- Country
- France
- Department
- Département de Cancérologie de l’enfant et de l’adolescent
Research Overview
Data & Insights
Has run more than one trial at 0 of 10 partner sites.
Specializations
Pediatric Acute Leukemia and Myelodysplastic Syndromes
The investigator concentrates on relapsed or refractory blood cancers affecting children and adolescents, integrating molecular insights into therapeutic choices.
- Relapsed Acute Myeloid Leukemia
- Pediatric Myelodysplastic Syndrome
- Therapeutic strategies for Acute Lymphoblastic Leukemia
- Targeting IDH1 mutations in pediatric AML
- Hematopoietic stem cell transplantation for high‑risk disease
Emphasis is placed on genomics‑driven precision medicine for these high‑risk hematologic entities.
MTAP‑Deleted Solid Tumors
Research focuses on cancers bearing homozygous loss of the MTAP gene, exploring targeted and combinatorial approaches across organ systems.
- Phase‑exploratory agents for MTAP‑deleted non‑small cell lung cancer
- Targeted approaches in MTAP‑deleted glioblastoma
- Combination strategies for MTAP‑deleted pancreatic adenocarcinoma
- Biomarker‑driven trials in MTAP‑deleted mesothelioma
- Therapeutic options for MTAP‑deleted sarcoma
Genomic selection guides patient enrollment in investigational regimens.
Rare Pediatric Solid Tumors
The investigator addresses low‑incidence embryonal and neuro‑endocrine malignancies, prioritizing age‑appropriate treatment and survivorship outcomes.
- Neuroblastoma with high‑risk features
- Rhabdomyosarcoma of extremities
- Ewing sarcoma with fusion‑driven biology
- High‑grade glioma (H3K28M) in children
- Medulloblastoma subgroups with molecular targets
Therapeutic protocols are adapted to pediatric pharmacokinetics and long‑term quality of life.
HER2 and EGFR Altered Cancers
Investigation spans HER2‑positive/low and EGFR‑mutated malignancies, integrating antibody‑drug conjugates and kinase inhibition.
- HER2‑positive breast and gastric cancers
- HER2‑low solid tumors
- EGFR‑mutated non‑small cell lung cancer
- Resistance mechanisms to HER2‑directed ADCs
- Novel HER2 kinase inhibitors in pediatric sarcomas
Efforts focus on overcoming therapeutic resistance and expanding targetable populations.
Immunotherapy in Pediatric Oncology
Exploration of checkpoint blockade and cellular immunotherapies aims to improve outcomes for refractory pediatric cancers.
- PD‑1 inhibition in relapsed solid tumors
- CTLA‑4 blockade combined with radiation
- Adoptive T‑cell therapy for leukemia
- Biomarker‑guided immune checkpoint trials
- Safety profiling of immune agents in children
Monitoring of immune‑related adverse events is integral to trial design.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.